08:57:35 EDT Sun 25 Oct 2020
Enter Symbol
or Name

Login ID:

Shell Summary for Oct. 31, 2019

2019-10-31 20:01 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange inched up a fraction to 538.37 Thursday, ending the month down 20.31 points. Charalambos (Harry) Katevatis has filed a preliminary prospectus to list his second capital pool shell, Zenith Capital Corp., with a $200,000 initial public offering at 10 cents. Its IPO agent is Canaccord Genuity Corp.

(There is another reporting issuer with exactly the same name. It is Donald McCaffrey's privately held Zenith Capital Corp. This company's wholly owned subsidiary, Zenith Epigenetics Ltd., is conducting clinical trials on a potential cancer treatment. Mr. McCaffrey also has a publicly held biotech company, Resverlogix Corp. (RVX: $1.19), which trades on the Toronto Stock Exchange.)

Mr. Katevatis's Zenith Capital sold two million escrow shares in April at the typically discounted price of five cents. Mr. Katevatis, 78, bought one million of the escrow shares. Also in April, his capital pool shell sold 500,000 non-escrow shares at the IPO price of 10 cents.

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2020 Canjex Publishing Ltd. All rights reserved.

Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.